Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133035 | 0.85 | ADORA3 (0.39) | LMNAADORA3HSD17B1MAPTTP53 | |
| SCHEMBL13055747 | 0.78 | NPC1 (0.45) | LMNAHSD17B1MAPTNPC1RAB9A | |
| SCHEMBL13056131 | 0.75 | NQO2 (0.33) | LMNAHSD17B1MAPTTP53RAB9A | |
| SCHEMBL13056184 | 0.73 | MEN1 (0.35) | LMNAHSD17B1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13055820 | 0.70 | HDAC1 (0.36) | LMNAHSD17B1MAPTTP53NPC1 | |
| SCHEMBL13056071 | 0.69 | KCNMA1 (0.54) | — | |
| SCHEMBL13055887 | 0.68 | KDR (0.36) | LMNAADORA3TP53NPC1RAB9A | |
| SCHEMBL15649255 | 0.63 | KDM4E (0.55) | LMNAADORA3MAPTTP53NPC1 | |
| SCHEMBL13075281 | 0.62 | GRM5 (0.39) | HSD17B1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17295638 | 0.61 | NQO2 (0.60) | LMNAMAPTTP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2010-11-18 | — | — | US | disclosed |
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | LMNA 3116/4885ADORA3 3532/4885HSD17B1 1742/4885 |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | LMNA 3116/4885ADORA3 3532/4885HSD17B1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.